Skip to content
Encepheal Therapeutics logo

Encepheal Therapeutics

Encepheal Therapeutics is a YC Summer 2019 (S19) company. Based in Winston-Salem, NC, USA. Team of 3.

  • Therapeutics
  • Drug discovery

About Encepheal Therapeutics

GPAgent's own fund-neutral profile, written from public information. Updated Oct 5, 2026.

Summary

Encepheal Therapeutics develops small-molecule drugs to treat stimulant addiction, targeting cocaine and methamphetamine use disorders for which no FDA-approved medications exist. Its lead compounds are atypical, allosteric inhibitors of the dopamine transporter, the same target cocaine acts on, designed to reduce craving and reinforcement without the abuse potential that derailed earlier dopamine-targeted therapies. The work replaces the current clinical gap where patients with stimulant use disorder have no pharmacological treatment options comparable to methadone or buprenorphine for opioid addiction.

From the Y Combinator listing

How Encepheal Therapeutics describes itself in Y Combinator's public directory. Original listing (opens in a new tab)

EncepHeal develops medications to treat substance abuse, starting…

EncepHeal is developing medications to treat substance abuse. Our first product is a small molecule therapeutic for stimulants like cocaine and methamphetamine, of which there are no FDA approved treatments. Our small molecule technology are atypical inhibitors of the dopamine transporter. Cocaine itself is an inhibitor of the same transporter. Directly reducing craving or positive reinforcement is a successful treatment strategy for addiction. Methadone or buprenorphine (Suboxone) are key examples of this for opioid use disorder. However, these types of medications can be addictive themselves. This has been a major hurdle for medication development for cocaine addiction and has led to many leaders in the addiction space to abandon the dopamine transporter as a target. At EncepHeal, we believe that the dopamine transporter should not be abandoned and instead focusing on fixing the abuse liability problem. Therefore with our partners at the National Institutes of Health, we have shown that these new, allosteric modulators at the dopamine transporter do not display addictive tendencies in animal models. They are also effective at curbing cocaine addiction. Our management team has two co-founders, Omeed Rahimi and Aaron Lazarus, as well as an experienced addiction pharmacologist as their research officer. The team has an advisory board with entrepreneurial and addiction drug development experience as well as expert partners at the National Institute on Drug Abuse, a subset of the NIH, and Wake Forest. Our team has had success in raising non-dilutive funding and has expertise with SBIR/STTR grants. We are looking for help in better connecting with the biotech/pharmaceutical industry.

Facts

Industry
Healthcare / Healthcare -> Therapeutics
Location
Winston-Salem, NC, USA
Team size
3
Status
Inactive
Stage
Early

Founders (2)

Score every batch against your own thesis

GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.

How Accelerator intelligence works